The concepts of his Guselkumab study are interwoven with issues in Clinical trial, Pregnancy outcomes and Family medicine. His Plaque psoriasis research focuses on subjects like Bimekizumab, which are linked to Adalimumab, Double blinded, Post-hoc analysis, Palmoplantar psoriasis and Nail psoriasis. His Psoriasis Area and Severity Index research incorporates elements of Body surface area and Randomized controlled trial. His Internal medicine study incorporates themes from Psoriasis Area and Severity Index and Placebo. He has researched Psoriasis in several fields, including Gastroenterology, Etanercept, Interleukin 17 and Phases of clinical research. The scientist’s investigation covers issues in Psoriasis, Internal medicine, Dermatology, Plaque psoriasis and Guselkumab. In recent papers he was focusing on the following fields of study: What were the highlights of his more recent work (between 2018-2021)? Secukinumab together with Interleukin 17.His Psoriasis Area and Severity Index study also includes In his work, Physical therapy is strongly intertwined with Quality of life, which is a subfield of Placebo. His research integrates issues of Tolerability and Pimecrolimus in his study of Dermatology. His work in Internal medicine addresses subjects such as Gastroenterology, which are connected to disciplines such as Tofacitinib and Janus kinase inhibitor. His Psoriasis research is multidisciplinary, incorporating elements of Adalimumab, Ustekinumab, Clinical trial, Surgery and Etanercept. Langley mainly focuses on Psoriasis, Internal medicine, Dermatology, Placebo and Psoriasis Area and Severity Index. What are the main themes of his work throughout his whole career to date? Adalimumab Therapy for Moderate to Severe Psoriasis: A Randomized, Controlled Phase III Trial (662 citations).A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.Secukinumab in plaque psoriasis-results of two phase 3 trials.In general Dermatology, his work in Atopic dermatitis is often linked to Quality of life linking many areas of study. The Tildrakizumab study combines topics in areas such as Guselkumab and Risankizumab. His Randomized controlled trial study integrates concerns from other disciplines, such as Body surface area and Clinical trial. Langley has included themes like Adalimumab, Secukinumab, Brodalumab, Gastroenterology and Etanercept in his Placebo study. His Psoriasis research integrates issues from Tolerability, Adverse effect and Surgery. Langley spends much of his time researching Internal medicine, Psoriasis, Placebo, Randomized controlled trial and Psoriasis Area and Severity Index. What is he best known for? The fields of study he is best known for:
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |